One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
- :
Price : 100$- Special Price : 50$
Lower body mass and lower adiposity are associated with differential responses to two treatment strategies for rheumatoid arthritis
doi : 10.1136/ard-2023-225014
Volume 83, Issue 4, April 2024, Pages 429-436
Effectiveness of longstanding exercise therapy compared with usual care for people with rheumatoid arthritis and severe functional limitations: a randomised controlled trial
doi : 10.1136/ard-2023-224912
Mortality in patients with psoriatic arthritis in Sweden: a nationwide, population-based cohort study
doi : 10.1136/ard-2023-224965
Male patients with inflammatory joint diseases are less likely than controls to be childless: results from a Norwegian population-based cohort study of 10 865 patients
doi : 10.1136/ard-2023-224998
Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression
doi : 10.1136/ard-2023-224919
Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial
doi : 10.1136/ard-2023-224854
CD7 activation regulates cytotoxicity-driven pathology in systemic sclerosis, yielding a target for selective cell depletion
doi : 10.1136/ard-2023-224827
CD19-targeting CAR T cells protect from ANCA-induced acute kidney injury
doi : 10.1136/ard-2023-224875
Clonal haematopoiesis across the age spectrum of vasculitis patients with Takayasu’s arteritis, ANCA-associated vasculitis and giant cell arteritis
doi : 10.1136/ard-2023-224933
Randomised trial of genetic testing and targeted intervention to prevent the development and progression of Paget’s disease of bone
doi : 10.1136/ard-2023-224990
Subclinical inflammation and joint damage progression in patients with early RA fulfilling 2011 vs 2022 ACR/EULAR Boolean remission criteria: data from the ARCTIC study
doi : 10.1136/ard-2023-224950
Low plasma belimumab levels as an indicator of poor adherence to belimumab in patients with systemic lupus erythematosus
doi : 10.1136/ard-2023-225023
Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis
doi : 10.1136/ard-2023-225174
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023
doi : 10.1136/ard-2023-224916
Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the ‘JAK-pot’ study)
doi : 10.1136/ard-2023-224670
